A liquid biopsy for metastatic prostate cancer

Researchers are developing tools for predicting how fast prostate cancer might progress; among the most promising are those that count circulating tumor cells (CTCs) in blood samples. Research shows that high CTC counts predict poorer survival and faster disease progression. But they are also predictive for early-stage metastatic prostate cancer that still responds to hormonal therapy.